Biogen: MS Treatment

To secure funding for an expensive MS drug and overturn a negative NICE appraisal, Spink developed a lobbying platform, 'Action for Access' to mobilise patients, engage with patient organisations, MPs and clinicians to drive a high profile media agenda.

With questions tabled in parliament, a 20 minute slot on Newsnight and 1,000 patients signed up to the campaign, funding was secured together with a groundbreaking partnership agreement between our client and the NHS.


Return to Pharmaceutical